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Background: Two long synthetic peptides representing the dimorphic and constant C-terminal domains of the
two allelic families of Plasmodium falciparum merozoite surface proteins 2 are considered promising malaria vaccine
candidates. The aim of the current study is to characterize the immune response (epitope mapping) in naturally
exposed individuals and relate immune responses to the risk of clinical malaria.
Methods: To optimize their construction, the fine specificity of human serum antibodies from donors of different
age, sex and living in four distinct endemic regions was determined in ELISA by using overlapping 20 mer peptides
covering the two domains. Immune purified antibodies were used in Western blot and immunofluorescence assay
to recognize native parasite derivate proteins.
Results: Immunodominant epitopes were characterized, and their distribution was similar irrespective of geographic
origin, age group and gender. Acquisition of a 3D7 family and constant region-specific immune response and antibody
avidity maturation occur early in life while a longer period is needed for the corresponding FC27 family response. In
addition, the antibody response to individual epitopes within the 3D7 family-specific region contributes to protection
from malaria infection with different statistical weight. It is also illustrated that affinity-purified antibodies against
the dimorphic or constant regions recognized homologous and heterologous parasites in immunofluorescence
and homologous and heterologous MSP2 and other polypeptides in Western blot.
Conclusion: Data from this current study may contribute to a development of MSP2 vaccine candidates based on
conserved and dimorphic regions thus bypassing the complexity of vaccine development related to the
polymorphism of full-length MSP2.
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One strategy of malaria intervention is the development
of a safe and effective blood-stage vaccine against
Plasmodium falciparum [1,2]. The complex life cycle
of P. falciparum, the wide range of blood stage proteins
and their extensive polymorphism provide many options
for vaccine design but also render selection of the appro-
priate antigen(s) and vaccine development challenging. To
overcome obstacles to vaccine development resulting from
antigen polymorphism, this study focused only on non- or
semi-polymorphic regions of promising vaccine candi-
dates [3-7]. One of these is merozoite surface protein 2
(MSP2), a blood-stage protein that appears to be essential
for viability and completion of the Plasmodium life cycle
in humans [8-11]. While its function is not known, it
induces specific antibodies (Abs) that are active in vitro
against parasite merozoites [12-14] and are associated
with protection in endemic areas.
MSP2 is a glycosylphosphatidylinositol (GPI)-anchored
protein present on the merozoite surface consisting of
about 200–250 amino acids, encoded by a single exon
on chromosome 2. It contains conserved N- and C-
terminal (C) regions flanking a highly polymorphic cen-
tral repeat region [15]. A non-repeat semi-conserved
dimorphic (D) region defines the two allelic families of
MSP2: 3D7 and FC27 [16]. D and C region families dis-
play low structural complexity due to the high percentage
of hydrophilic residues, and are predicted and shown to
represent “intrinsically unstructured regions” [4,17]. It has
been shown that specific semi-immune Ab against MSP2
protein is predominantly cytophilic IgG3, as in other
blood stage proteins [4,12,13,18]. These cytophilic (IgG1
and IgG3) Abs are thus thought to play an important role
in antibody-mediated mechanisms of parasite clearance
[19,20].
A full-length recombinant MSP2 protein was tested in
clinical trials as one of the constituents of a three-
component malaria vaccine, Combination B [21,22], con-
taining ring-infected erythrocyte surface antigen (RESA),
MSP1 and MSP2 (3D7 variant). The product was safe and
partially protective. This effect was, at least in part, due to
the immune response against the MSP2-3D7 allele. The
3D7-MSP2 vaccinated group had lower prevalence of par-
asites carrying this allelic form, while a higher incidence of
morbidity episodes was associated with heterologous
FC27-type infections [21-24]. These findings suggested
that: i) inclusion of both allelic families in a MSP2-based
vaccine should increase its efficacy, and ii) an immune re-
sponse against the highly variable repeat region of MSP2
was probably not involved in protection from 3D7 parasite
infection, since the 3D7 repeat present in the vaccine was
found very rarely in MSP2 variants in the study area. In
a recent phase I clinical trial, a recombinant vaccine
candidate containing both the 3D7 and FC27 full-lengthproteins showed that the majority of vaccinated subjects
elicited Abs that were specific for both forms of MSP2
and active in inhibiting parasite growth in antibody-
dependent cellular inhibition (ADCI) [25].
In our own investigations only D and C domains of
both MSP2 allelic variants were considered, due to the
high polymorphism of the central region of MSP2, while
the non-polymorphic N-terminal region was excluded
because it favours amyloid fibril formation within the
MSP2 molecule [26] which potentially leads to regulatory
issues. The choice of D and C domains was motivated by
the finding showing that the Abs against the 3D7 family
specific and constant domain (D +C) was associated with
protection from clinical malaria and were active in ADCI
[4,12,23]. The present study used overlapping 20-mer pep-
tides and donors from different endemic areas, varying by
age and sex to identify fragments within the D and C re-
gions with promising vaccine potential.
Methods
Synthetic peptides
The schematic structure and full-length sequence align-
ment of the two allelic families of MSP2 are shown respect-
ively in Figures 1A and 1B. All peptides were synthesized at
the Department of Biochemistry, University of Lausanne,
Switzerland, using an Applied Biosystem 431A instrument
(Foster City, CA, USA) and Fmoc chemistry and capping of
the unreactive peptide chains with acetic anhydride at each
cycle. The purity of each peptide (>80%) was determined
using analytical C18 HPLC and mass spectroscopy. Ly-
ophilized peptides were dissolved in phosphate buffered
saline (PBS (Gibco® Invitrogen™)) at a concentration of
1 mg/ml [4]. Different LSPs derivate from both allelic
families of MSP2 are represented in Additional file 1. Over-
lapping 20-mer peptides (overlapping by ten amino acids)
were synthesized by using the MultiRespep Synthesizer
(Bioanalytical Instrument, Intavis AG). Thus, 12 20-mer
peptides (P11-P22) and eight 20-mer peptides (P23-P30)
covered, respectively, 3D7 and FC27-MSP2 D +C region.
Thus, the 3D7 20 mers P20, P21 and P22 are similar to
the FC27 20 mers P28, P29 and P30. Peptides P19 (from
3D7 family) and P27 (from FC27 family) contained the
eight last aa of the D regions, respectively, plus the 12 first
aa of their C region (Figure 1C).
Human plasma
Human sera or plasma samples were collected during
the malaria transmission season in each endemic area.
Adult donors were from Burkina Faso (BF), Papua New
Guinea (PNG), Tanzania (TZ), Nigeria (NG). Donors from
Mali were categorized into three age groups (≤five years,
six to 14 years and ≥15 years).
For the analysis of association of antibody responses with
protection two hundred and eighty sera from children of
Figure 1 Schematic structure, full-length alignment sequence, and overlapping 20 mers covering D and C regions of MSP2. A) Represents
schematic structures of merozoite surface protein 2 (MSP2) with different domains (modified from Flueck et al. [4]). Mature MSP2 consists about 200–250
amino acids and contains two conserved domains (black, N-and C-termini) flanking a polymorphic region that includes repetitive sequences (light grey)
and a non-repetitive dimorphic domain (dark grey). The lengths of the non-conserved domains are strain-dependent. The dimorphic region defines two
allelic families of MSP2, 3D7 and FC27. B) Shows sequence of the two allelic full-length sequences (from N-to C-terminal) of MSP2 (3D7 and FC27).
Non-repeat family-dimorphic regions are shaded in light gray, conserved (N- and C-termini) sequences are underlined. The non-shaded and
non-underlined sequences represent the polymorphic regions. C) Shows sequence of Dimorphic and constant C-region (blue) sequences, and
overlapping 20 mers covering the two regions. In parentheses is the sequence position number. LSP: long synthetic peptide.
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were available. These children formed the placebo group of
an SPf66 vaccine efficacy trial [27]. All illness episodes in
these children reporting to the local health centre during a
one-year follow-up after collection of these sera were re-
corded, and malaria slides prepared for determination of
parasite positivity and densities. For analysis of the relation-
ship of protection to antibody levels a clinical malaria
episode was defined as measured fever (> or = 37.5 de-
grees C) and parasite density > 20,000/microL. This was
the same definition as was used in the original trial[27]. Research and ethical clearance was granted by the
Tanzanian Commission for Science and Technology
(UTAFITI NSR/RCA 90).
Sera from Swiss naive donors (12 to 13 individual do-
nors) who had no malaria history were used as a negative
control. Blood was taken by venipuncture into tubes con-
taining EDTA according to the ethical clearances of each
country. Research carried out on humans was conducted
in compliance with the Helsinki Declaration. Some donors
with high Ab titres were selected in single or pooled to
purify Abs (pAbs) reactive to D, C and D +C fragments of
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of 3D7 family.
Affinity purification of human polyclonal antibodies
Reactive Abs to FC27-D + C, 3D7-D + 8aa C, 3D7-D,
FC27-D and C LSPs were purified from ELISA positive
plasma from BF, PNG, NG adults and different age groups
from Mali using affinity chromatography as previously de-
scribed [28]. Briefly, 5 mg of peptides were added to 1 ml
of activated sepharose and processed according to manu-
facture instructions.
Enzyme-linked immunosorbent assay
For enzyme-linked immunosorbent assay (ELISA), antigen
concentration for coating 96-well flat plates (BD Biosci-
ences) was 1 μg/ml for peptides longer than 40 residues,
and 5 μg/ml for peptides shorter or equal to 40 residues.
As previously described [5,28,29], plates were coated
overnight (O/N) with 50 μl of peptide at the appropriate
concentration in PBS and then blocked for one hour at
room temperature (RT) in PBS containing 5% non-fat
milk powder. Test was considered positive if the sample
OD mean was ≥OD mean + 3 SD of negative controls
(non-exposed Swiss donors) or if the ratio of sample OD
mean divided by OD mean of negative controls was ≥2.
Each sample was tested in duplicate.
Antibody avidity
A native protein is characterized by its folded structure;
increasing the chaotropic characteristics of solvent leads
to denaturation. Guanidine chloride (GdCl, Merck KGaA,
Darmstadt, Germany) is one of the general protein dena-
turants leading to protein unfolding [30,31]. Briefly, for
measuring Ab avidity by ELISA, different concentrations
of GdCl (8 M, 4 M, 2 M, 1 M and 0 M) were mixed with
plasma for 30 min before transferring the mixture into
peptide-coated plates. Relative avidity was determined by
the concentration of GdCl needed to obtain 50% of the
OD value in the absence of GdHCl. Thus samples with
OD at 1 M GdHCl higher or equal to 50% of the OD in
the absence of GdHCl (0 M) were considered having
higher avidity than those with less than 50% of the OD in
the absence of GdHCl.
Immunofluorescence and Western Blot
Immunofluorescence assay (IFA) was performed on blood
smear slides containing at least 5% schizontes of 3D7 and
FC27 P. falciparum cultures and Western blot (WB) were
performed using reduced 3D7 and FC27 parasite lysates
[5,28].
Statistical analysis
Pearson’s Chi-square or Fisher’s exact tests were used to
assess association between categorical variables andANOVA tests (GraphPad Prism, version 5.00) were used
to test differences between groups in antibody levels. The
relationship between antibody-levels measured in ELISA
and the incidence of clinical malaria in the Tanzanian chil-
dren was evaluated by Kaplan Meier analysis, including
tests of significance using log rank chi-square tests. The
effects were tested both with age-adjustment, and without
adjustment for age.Results
Recognition of individual domains by human sera and
delineation of B cell epitopes
The intrinsically unstructured D and C offers an ideal
opportunity to study the fine specificity of MSP2-reactive
human Abs using long and/or short overlapping peptides.
The lengths of different LSPs covering D and C regions of
the two allelic family regions are showed in Additional
file 1. Purified Abs (pAbs) reactive with D + C of each al-
lelic family (obtained from Nigerian adult pooled plasma)
and tested in ELISA showed that each dimorphic derivate
and C region LSP was well recognized. However, 3D7-D
LSP was better recognized than that of C region while
the contrary was observed for FC27-D LSP, respectively
(Figure 2A and B). Cytophilic IgG1 and IgG3 were the
most prevalent subclasses recognizing the 3D7-D and C
LSP while recognition of FC27-D LSP was mainly asso-
ciated with IgG1 (Additional file 2).
In order to study the fine specificity of the antibody
response outlined above, 20-mer peptides (overlapping by
10 aa) covering the two allelic regions, D and C regions of
MSP2 were tested.
First, sera of adults living in four different endemic re-
gions were tested in ELISA to see if MSP2 20 mers were
equally recognized. The prevalence (% positive samples in
ELISA test), OD and SD of Ab responses for each peptide
are shown in Table 1. The most frequently recognized 20
mers in the 3D7-D region were P13, which was recog-
nized by 67 and 51% of donors from PNG and TZ, re-
spectively, and P13/16, recognized by 46% of the donors
from Mali, as well as P17 recognized by 69% from BF. For
the FC27-D region, the most prevalent 20 mers were P23
with 48% in PNG, P25 with 45 and 18%, respectively in BF
and in Mali, and P26 with 51% in TZ. For the C region,
P29 appeared the most prevalent in PNG (50%), BF (39%)
and in Mali (13%) while in TZ the most frequent was P30
with 43% (Table 1). Overall, considering the overall preva-
lence in the four areas, P13 (51%) and P16 (48%) were the
most prevalent for the 3D7-D; P23 (28%) and P25 (31%)
were for the FC27-D, and P29 and P30 (30%) for C-region
(Table 1). However, the frequency of recognition of these
commonly seen 20 mers, except for P13 (immunodominant
epitopes) differed significantly among the four endemic
areas (p <0.05). At all sites, 3D7-D was more frequently
Figure 2 D+C long synthetic peptides purified antibodies from immune adult recognized D and C. ELISA was performed using LSPs covering
D + C or D and C fragments of the two MSP2 allelic families and purified antibody (pAb) from immune adult pooled sera from Nigerian donors. A and
B represent, respectively, LSP representing 3D7 and FC27 allelic families. The mean of the OD at a dilution 1/100 was determined. A and B show
one-way ANOVA tests comparing the immune response (OD) to the 3D7-D and FC27-D regions to those to the C region respectively.
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quency was similar among FC27-D and C regions
(Table 1).
These data showed that all 20-mer peptides were anti-
genic and led to the delineation of immunodominant
MSP2 epitopes in endemic areas tested.
Fine specificity of D and C region recognition in different
age groups
Epitope mapping was extended to donors divided into
three age groups (children ≤ five years, adolescents six to
14 years and adults ≥15 years) living in Mali. Samples
were collected during the malaria transmission season. The
prevalence of the most recognized 20 mers of the 3D7-D
and C domains did not depend on the age of donors
(Table 2). In contrast, for the FC27-D region, acquisition of
immune responses against the 20 mers increased signifi-
cantly with age, in particular, there were significant differ-
ences between the children and adults children (Table 2).
In the context of this evidence that immune responses
against the D and C regions are acquired early in indi-
viduals exposed to malaria, the detailed age profile of
immune response acquisition in the earlier life of donors
was examined in the 186 sera from Tanzanian children
of different ages (one to five years). Immune responses
against most of peptides increased with age until two to
three years old, but tended to decrease in four years old
children. Thereafter Ab responses remained stable or
increased again (Figure 3A). A similar pattern of Ab
responses was observed also for LSPs covering D + C
region of the two MSP2 allelic families, the C region
alone (Figure 3B). To determine if this was a general
phenomenon, other unstructured LSPs derived from a
blood or pre-erythrocytic stage proteins, PFF0165c, P27A,
MR252 [5], exported proteins PfEXP1, MR127B [32,33],
and N-terminal circumsporozoite (CS) protein fragments
(MR48 and MR48A [34]) (Additional file 1) were tested inELISA. Interestingly, only Ab responses against LSPs from
MSP2 increased with age until two to three years followed
by a modest decrease in four years old while those to
EXP1, CS and P27A LSPs tended to increase or remain
stable at this age (Figure 3B).
Relative avidity of antibodies to D- and C-LSPs and their
immunodominant epitopes in different age groups
Antibody avidity is one of the parameters used to deter-
mine the maturation of an immune response [35-39].
Relative avidity of Abs reactive to different fragments of
MSP2 and their 20 mers was determined by using differ-
ent concentrations of GdCl at a fixed serum dilution
(1:200) in ELISA (data not shown). Eleven plasma samples
per age group from Malian donors that gave the highest
OD in ELISA against D and C were tested. By considering
the OD value curve at different concentrations of the
GdCl (i.e., the number of samples with OD at 1 M GdCl
higher than 50% of the OD at no GdCl), the relative
avidity between the 3D7-D LSP and its specific Ab ap-
peared similar for different age groups as shown in
Additional file 3A. In contrast, relative avidity for FC27-D
specific Abs was low in children and increased with age
(children < adolescents < adults, (children versus adults,
p <0.05 (*)) (Additional file 3B)) whereas, relative avidity
of Abs for the C region was higher in children compared
to adolescents and adults (p <0.05 (*) and P ≤ 0.001 (**),
respectively) (Additional file 3C). These results are consist-
ent with those obtained above regarding age dependency of
immune responses.
Association of the immune antibody response elicited
against individual 3D7-D 20 mers in children with
protection from malaria
It has been shown earlier [4] that the antibody response
to 3D7 D + C but not FC27 D + C region is associated
with protection from malaria clinical malaria. In addition,
Table 1 MSP2 D and C domain epitope mapping in different endemic areas
Peptides PNG (N = 42) Tanzania (N = 37) BF (N = 49) Mali (N = 39) Sum of
positves: n (%)
p value
Positive:
n (%)
OD
mean
SD Positive:
n (%)
OD
mean
SD Positive:
n (%)
OD
mean
SD Positive:
n (%)
OD
mean
SD
3D7 family D 41 (98) 2.24 1.29 33 (89) 1.47 1.29 49 (100) 2.01 0.74 38 (97) 1.75 1.32 161 (96) 0.058
P11 2 (5) 0.28 0.11 5 (14) 0.22 0.09 13 (27) 0.42 0.69 4 (10) 0.14 0.07 24 (14) 0.011
P12 13 (31) 0.55 0.61 8 (22) 0.30 0.25 16 (33) 0.49 0.53 16 (41) 0.49 0.91 53 (32) 0.120
P13 28 (67) 0.85 1.03 19 (51) 0.53 0.95 19 (39) 0.61 0.78 18 (46) 0.54 0.91 84 (50) 0.125
P14 19 (45) 0.64 0.68 10 (27) 0.50 0.83 28 (57) 1.09 1.25 10 (25) 0.29 0.43 67 (40) 0.003
P15 17 (40) 0.60 0.67 9 (24) 0.40 0.60 22 (45) 0.82 0.95 10 (25) 0.40 0.60 58 (35) 0.107
P16 14 (33) 0.60 0.64 9 (24) 0.57 1.19 27 (55) 0.85 0.84 18 (46) 0.60 0.89 68 (41) 0.028
P17 8 (19) 0.30 0.27 10 (27) 0.47 0.92 34 (69) 0.96 0.93 6 (15) 0.24 0.24 58 (35) <0.001
P18 1 (2) 0.24 0.07 13 (35) 0.28 0.23 14 (29) 0.48 0.68 5 (13) 0.23 0.50 33 (20) 0.001
P19 3 (7) 0.22 0.10 8 (22) 0.25 0.23 3 (6) 0.23 0.17 4 (10) 0.18 0.24 18 (11) 0.115
FC27 family D 40 (90) 1.21 0.82 31 (84) 1.01 0.81 42 (86) 1.47 1.11 25 (65) 0.72 1.06 138 (83) 0.009
P23 20 (48) 0.40 0.49 7 (19) 0.23 0.11 16 (33) 0.64 0.88 5 ()13 0.28 0.69 48 (29) 0.002
P24 3 (8) 0.24 0.22 3 (8) 0.19 0.17 11 (22) 0.32 0.21 4 (10) 0.27 0.49 21 (12) 0.114
P25 15 (36) 0.39 0.58 9 (24) 0.44 0.50 22 (45) 0.54 0.63 7 (18) 0.17 0.12 53 (32) 0.035
P26 17 (40) 0.32 0.29 11 (30) 0.36 0.58 11 (22) 0.33 0.31 5 (13) 0.16 0.11 44 (26) 0.018
P27 3 (8) 0.17 0.06 4 (11) 0.27 0.44 4 (8) 0.25 0.11 2 (5) 0.17 0.26 13 (8) 0.806
C region C 29 (69) 0.57 0.31 26 (70) 0.58 0.62 33 (67) 0.76 0.67 16 (41) 0.34 0.31 104 (62) 0.061
P28 2 (5) 0.20 0.10 0 (0) 0.22 0.05 4 (8) 0.23 0.13 1 (2) 0.16 0.17 7 (4) 0.384
P29 21 (50) 0.40 0.31 7 (19) 0.41 0.56 19 (39) 0.41 0.32 5 (13) 0.15 0.08 52 (31) 0.001
P30 16 (38) 0.23 0.11 16 (43) 0.40 0.64 13 (27) 0.39 0.39 5 (13) 0.19 0.17 50 (30) 0.017
Table 1 Showed ELISA performed on LSPs and 20 mers covering the D and C fragments of the two allelic families of MSP2. Adult plasma from PNG (N = 42), TZ (N = 37), BF (N = 49) and Mali (N = 39) were obtained
during malaria season transmission. ELISA was considered positive if the ratio of mean OD of test sample/mean OD of negative control was more than or equal to 2. Peptides in bold indicate the major recognized 20
mers. Means of Ab OD, standard deviation (SD), and p-values from Chi-square tests (comparing the proportion of responders among the four endemic areas for each peptide) were determined. P values ≤ 0.05 are in
bold and considered statically significant.
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Table 2 MSP2 D and C domains epitope mapping in different age groups
Peptides Children (1) (≤5 years)
N = 38
Adolescents (2) (6–14 years)
N = 43
Adults (3) (≥15 years)
N = 26
p value
Positive:
n (%)
Mean
OD
SD Positive: n
(%)
Mean
OD
SD Positive:
n (%)
Mean
OD
SD
1 v 2 1 v 3 2 v 3
3D7 family D 32 (84) 1.26 0.97 43 (100) 1.50 1.35 26 (100) 2.05 0.94 0.008 0.008 1
P11 0 (0) 0.11 0.01 2 (5) 0.12 0.02 8 (31) 0.17 0.11 0.148 0.001 0.007
P12 8 (21) 0.20 0.09 18 (42) 0.66 0.94 8 (31) 0.41 0.37 0.038 0.386 0.346
P13 16 (42) 0.64 0.95 20 (47) 0.44 0.73 11 (42) 0.40 0.37 0.690 0.987 0.733
P14 11 (29) 0.16 0.07 12 (28) 0.18 0.13 13 (50) 0.51 0.66 0.918 0.086 0.065
P15 13 (34) 0.18 0.13 24 (56) 0.39 0.53 9 (35) 0.59 0.83 0.045 0.973 0.078
P16 13 (34) 0.43 0.54 19 (44) 0.67 0.93 12 (46) 0.53 0.70 0.356 0.337 0.874
P17 5 (13) 0.20 0.16 22 (51) 0.21 0.16 7 (27) 0.29 0.35 <0.0001 0.181 0.036
P18 2 (5) 0.14 0.08 2 (5) 0.13 0.02 6 (23) 0.33 0.56 0.899 0.048 0.038
P19 14 (37) 0.22 0.31 4 (9) 0.11 0.01 2 (8) 0.20 0.27 0.002 0.002 0.814
FC27 family D 23 (61) 0.21 0.11 37 (86) 0.85 1.15 23 (88) 0.76 0.50 0.007 0.006 0.768
P23 2 (5) 0.11 0.02 12 (28) 0.50 0.94 9 (35) 0.15 0.06 0.003 0.003 0.562
P24 0 (0) 0.14 0.04 4 (9) 0.45 0.83 7 (27) 0.21 0.13 0.036 0.002 0.071
P25 4 (11) 0.13 0.05 7 (16) 0.20 0.17 10 (38) 0.19 0.12 0.444 0.009 0.045
P26 4 (11) 0.11 0.02 10 (23) 0.18 0.17 8 (31) 0.17 0.08 0.118 0.050 0.499
P27 6 (16) 0.21 0.36 6 (14) 0.11 0.02 2 (8) 0.20 0.29 0.817 0.305 0.400
C region C 14 (37) 0.27 0.28 19 (44) 0.25 0.12 14 (54) 0.50 0.40 0.500 0.175 0.435
P28 6 (16) 0.17 0.21 2 (5) 0.13 0.02 3 (23) 0.19 0.22 0.098 0.473 0.038
P29 5 (13) 0.12 0.04 11 (26) 0.13 0.04 8 (31) 0.18 0.11 0.150 0.096 0.644
P30 2 (5) 0.13 0.05 5 (12) 0.13 0.03 7 (27) 0.28 0.26 0.296 0.022 0.125
Table 2 showed ELISA performed on LSPs and 20 mers covering the D and C fragments of the two allelic families of MSP2 using sera from age groups living in Mali. Plasma was used at dilution 1/200. The ELISA was
considered positive if the ratio of mean Ab OD of test sample/mean OD of negative control was more than or equal to 2. Ab OD, SD and p-values from Fisher’s exact test (comparison of the proportions positive
between two age groups) were calculated for each peptide. Numbers (1, 2, 3) represent respectively children, adolescents and adults code. v: versus. P values ≤ 0.05 are in bold and considered statically significant.
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Figure 3 Acquisition of immune response against D and C regions of MSP2 occurs early in life in malaria-exposed donors. Sera from
children of different ages (1–5 years old) living in Tanzania were collected and used in direct ELISA. A) Shows age dependent recognition of
3D7-D and its 20 mers peptides (N: number total of children = 186). B) Shows age dependent recognition of different LSPs representing P27A
(MR252; N = 208), exported protein 1, EXP1 (MR127B; N = 254) and CS (MR48A, MR48; N = 254). Sera were used at dilution of 1/200.
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served residues was also associated with protection in the
Tanzanian children cohort. This analysis was then ex-
tended to 3D7-D LSP and its corresponding 20 mers in
the same Tanzanian children. The relationship between
malaria morbidity and antibody OD at baseline was deter-
mined for each peptide. Peptides P11, P12, P13 and P16
were associated with the highest probability in protection
(Figure 4A). Except for P11, the peptides P12, P13 and
P16 were among the immunodominant epitopes of 3D7-D
as shown above in Table 1. These epitopes showed a
slightly increased or similar association with protection
compared to the reference LSP of 3D7-D. However, their
association with protection was not statistically significant
(p >0.05) (Figure 4A).
Since peptides P11, P12 and P13 showed the strongest as-
sociation with protection, a longer peptide, called P2604
(111–150; 40 aa) containing the three sequences was syn-
thesized. ELISA test performed in the cohort of Tanzanianchildren indeed showed an increased recognition P2604, but
the association with protection did not reach a significance
level (Figure 4B and C) for either peptide P2604 or D.
Cross-reaction of D- and C-LSP purified antibodies in WB
and IFA
As reported previously [14], 3D7-D and FC27-D human
reactive Abs inhibited heterologous parasite growth as
determined in ADCI and recognized heterologous MSP2
recombinant proteins in ELISA. To confirm these find-
ings, analysis was extended using 3D7-D, FC27-D and C
LSP affinity purified Abs from single adult BF donors. In
WB, the FC27-D pAbs recognized only family-specific
proteins whereas 3D7-D pAbs recognized both 3D7 and
FC27 P. falciparum-derived proteins (Figure 5A and B).
Cross-reactive bands observed were depending on serum
donor (Figure 5A). As expected, the C region-reactive
pAbs recognized both 3D7 and FC27-strain derived mer-
ozoite proteins (Figure 5C). Note that MSP2 is localized
Figure 4 Association of antibody response against 3D7-D 20 mers and protection from malaria in children. Sera from children 1–5 years old
(N = 186) living in Tanzania were used at dilution 1/200 to perform ELISA on 3D7-D LSP and its corresponding 20 mers. A) Log rank chi-squares statistics
from Kaplan-Meier analysis testing the association of malaria morbidity rates with adjusted Ab OD for age. The p values (p) test the hypothesis that the
3D7-D and each 20-mer specific antibodies are associated with clinical protection. Since peptides P11, P12 and P13 showed the highest likelihood
association values with protection, P2604 containing those three 20 mers sequences was synthesized and tested in children 1–5 years old (N = 190)
living in Tanzania with its constitutive 20 mers, 3D7-D and 3D7D − + 8aaC. B) Shows profile curve of Ab responses (arithmetic mean OD). C) Shows
Log rank Chi-square from Kaplan-Meier analysis determining the relationship between malaria morbidity, Ab OD and age for each peptide.
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plasma pools of donors of different ages and single adult
C-reactive pAbs were used to perform IFA on both of
the 3D7 and FC27 schizonts. All of the 3D7-D specific
pAbs recognized both homologous (3D7) and heterol-
ogous (FC27) merozoites confirming the cross-binding
reaction (Additional file 4A and B). Due to the low level
of antibody titre against the FC27-D region found in
children and adolescents, the reverse experiment could
not be performed. As for WB, C region-reactive pAbs
recognized both 3D7 and FC27 parasites in IFA (Additional
file 4C).
Discussion
The aim of the current studies was the delineation of
immunodominant and protective D and C epitopes in
individuals living in different malaria-endemic areas in
order to develop more effective MSP2-based universal
vaccines either as a single candidate or in combination
with other antigens.
Here, the first observation was that the immunodomi-
nant 20-mer epitopes contained in each single MSP2 do-
main (P13, P15/16 for 3D7-D; P23, P25/P26 for FC27and P29/P30 for C) are in part conserved in the four
endemic areas analysed (Table 1). Differences in the level
and specificity of serum or affinity purified antibodies of
single individuals are observed and may depend on the
history of infections by different P. falciparum variant
strains and/or on the genetic diversity of donors [16,40,41].
In general, recognition of the 3D7-D major epitopes is
more prevalent than that observed for FC27-D and C re-
gions (Table 1) in agreement with data shown by other
groups either for the full-length proteins or fragments
thereof [3,4,7]. In addition, Ab responses against D or C
region of each MSP2 allelic family and individual 20 mers
were similar in male and female populations living in the
same endemic area (Additional file 5), thus facilitating the
development of universal MSP2-based vaccines.
The acquisition of an optimal response as judged by
ELISA is obtained early in life (age two to three years)
for the 3D7-D and its 20 mers as seen for several pre-
erythrocytic and erythrocytic antigens (Figure 3A, B).
This is further confirmed when the relative avidity of the
Ab response in the three age groups was determined. In
contrast, for the FC27-D region, as observed for the
magnitude of the response, the apparent avidity of Ab is
Figure 5 D and C affinity purified antibodies recognized polypeptides from the two allelic family of MSP2. Western Blot (WB)
was performed using 3D7 and FC27 merozoites. A and B show respectively, specific 3D7- and FC27 D-individual adult pAbs (Burkina
Faso, BF) against MSP2 allelic-derived polypeptides in WB, used at dilution of 1/100. Naive human sera (NHS) and C+ (pAb from
3D7-D + 8aa C) from Nigerian adult pool plasma were used as negative and positive controls, respectively. C) The C-terminal reactive-pAb
from individual BF donor (that gave highest Ab titre in ELISA) was obtained to perform WB on both MSP2 allelic family parasites at a dilution
of 1/100.
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file 3). Together, these data confirm that the response to
3D7 MSP2 matures earlier in life compared to that to
FC27 MSP2, most likely due to a higher rate of infection
by 3D7-family parasites [7,42,43]. In addition, the rela-
tive avidity of Abs against C region appeared strongest
in children compared to that shown in adolescent and
adult groups (Additional file 3). This confirms observa-
tions from other groups who showed that the positive
Ab responses to C-region were observed only in children
and not in adults [44-46].
Antibodies to P. falciparum MSP2 antigens belong
predominantly to the cytophilic and complement-fixing
subclasses IgG1 and IgG3, and have been shown to be
associated with protection from clinical malaria in im-
mune adults [13,47,48]. This study confirmed that IgG1
and IgG3 are the most relevant subclasses associated
with MSP2 LSP recognition in adults, but also in adoles-
cent and children (Additional file 2).
As described before [10,14,49,50], 3D7- and FC27-D
pAbs recognize the heterologous RecMSP2 (recombin-
ant MSP2 protein) in ELISA and here parasite-derived
proteins in WB and IFA (Figure 5, Additional file 4).
The cross-binding between the two allelic MSP2 familiesoccurred only between MSP2 full-length recombinant
proteins or parasite-derived proteins but not for LSP.
Moreover, the cross binding was strictly dependent on the
donors, suggesting a possible influence of parasite infec-
tions experienced by single donors and/or individual
genetic differences. Cross-binding with higher molecular
weight protein(s) was also observed using mouse sera or
monoclonal antibodies derived by mouse immunization
with MSP2 peptides [50]. Bio-informatic analysis indicates
a number of possible cross-reacting proteins (Additional
file 6), and proteomic experiments are needed to identify
them. As expected, C region specific pAbs recognized
both allelic parasite-derived proteins, further justifying its
inclusion in a MSP2 vaccine development. The extensive
cross-reaction discussed above may be beneficial for the
acquisition of a protective immune response.
Finally, the association of the Abs response to 3D7-D
region and its epitopes with protection from clinical mal-
aria was not statistically significant (p >0.05) but showed a
diverse degree of probability, with P11, P12 and P13 mers
having the highest probability. Analysis of the fragment
P2604 containing the P11, P12 and P13 sequences led to
increased recognition by Ab in different age groups (com-
pared to single constitutive 20 mers) but was not
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same cohort for the antigen D +8aaC gave smaller esti-
mates of relative risk, suggesting that the promising result
previously obtained may well be a chance finding. Thus,
testing of other paediatric cohorts is needed to assess the
impact of D + 8aaC in protection.
Conclusion
Previous [4,14,50] and present data further support the
notion that family-specific and constant regions of MSP2
are promising vaccine candidates, which should bypass
the limitations of using the full-length, highly polymorphic
MSP2 proteins as vaccines.
Additional files
Additional file 1: Sequences of different long synthetic peptides.
The bold and underlined sequences correspond to the common C-terminal
region sequence of MSP2-3D7 and FC27 families. 3D7 dimorphic derivate
LSPs are 3D7-D (88 aa), 3D7-D-M4 (73 aa) and 3D7-D-MR274 (60 aa). D + C is
sequence derivate from dimorphic of each family plus the C region. Note
that M and MR plus different number represent only peptide code given
during synthesis. Sequences of LSPs derivate from PfEXP1 (MR127B),
PFF0165C (MR252 or P27A) and P. falciparum circumsporozoite: PfCS
(MR48, MR48A from N-terminal) are also represented.
Additional file 2: Isotyping of IgG against D and C domain LSPs of
the two allelic families of MSP2. D and C fragments of the two MSP2
allelic families were used to perform ELISA in order to define the subclass
of total IgG. Individual plasma samples from children (N = 12), adolescents
(N = 13), and adults (N = 14) living in Mali were used at a dilution of 1/200.
ELISA was considered positive if mean of Ab OD of test sample with
considered IgG subtype was more than mean OD + 3SD of negative control
sera (N: 12). Percentage of positive sera for IgG1, IgG2, IgG3 and IgG4
against each region of MSP2 was thus determined.
Additional file 3: Determination of relative age-specific antibody
avidity against D and C regions. Plasma from different age groups
(children, adolescents and adults from Mali, 11 sample per age group)
that elicited high Ab responses in ELISA were mixed with different
concentrations of GdCl (0 to 8 M) for 30–45 minutes before transfer to
ELISA plates containing corresponding peptide. A, B and C represent
respectively, the relative Ab avidity to 3D7-D, FC27-D and C region LSPs.
The p values show statistic difference (Fisher’s exact test) between two
age groups. ns: not statistically significant, *: p < 0.05 and **: p ≤ 0.001.
Additional file 4: 3D7-D and C LSP purified antibodies recognized
merozoite proteins derived from the two allelic family parasites.
Immunofluorescence staining of malaria-infected erythrocytes was performed
with age specific 3D7-D (A, B) respectively y, 3D7 and FC27 strain merozoites,
and C-terminal reactive pAbs (C). The age reactive pAbs specific to 3D7-D
and C were obtained from age-pooled plasma (A and B), respectively and
single BF plasma (C), and used at a dilution of 1/100. Nucleus stained with
DAPI (in blue) and transmission picture of the infected red blood cell (DIC).
Additional file 5: D and C epitope prevalence of the two allelic
MSP2 according to the gender of donors. Plasma of Malian donors
(regardless of age): females (F, N = 57) and males (M, N = 50) were
collected during the malaria season transmission and used at dilution 1/
200 to perform direct ELISA on 20 mers covering the two domains of the
two MSP2 allelic families. Sample was considered positive responder if
ratio of mean Ab OD/mean OD of negative control was equal to or more
than 2. The p value was calculated from Fisher’s exact test that compares
variation between the two sexes for each peptide (n = number;%:
percent of positive donors). N = total number of donor from each sex.
Additional file 6: Similar shared sequences between the two allelic
families of MSP2. Similar possible and shared sequences are presented
here in order to explain the cross-binding occurred between the twoallelic families. For this purpose, dimorphic sequences of each MSP2 allelic
family were matched with those representing the heterologous family. A
and B represent, respectively, sequences of FC27 and 3D7 dimorphic
matched with their own and heterologous sequences, whereas C shows
matching of common C-terminal sequences with the two allelic regions
(minimal epitope is four amino acids). Upper case letter indicates the same
amino acids; lower case letter represents the different amino acids. All data
were generated from PlasmoDB database [51].
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